During Breast Cancer Awareness Month, IceCure’s VP of Business Development and Global Marketing, Tlalit Bussi Tel Tzure, was featured in a Forbes Business Development Council Article entitled “Breast Cancer Awareness Month: How Care Has Transformed in 2020.” The article shares Tlalit’s firsthand insights on how the health system, faced with unprecedented challenges during the COVID-19 pandemic, has […]
“None of the treated tumor lesions demonstrated contrast enhancement or growth on follow up imaging indicating a 100% oncologic success.” The full research was published in the Journal of Molecular and Clinical Medicine and conducted by Bnai Zion Medical Center in Israel by Dr. Sagi Shprits, Dr. Robert Sachner, Prof Ofer Nativ and Dr Sarel […]
In this article, IceCure’s VP Business Development and Marketing, Tlalit Bussi Tel-Tzure’s discusses healthcare innovation in the time of COVID-19. The healthcare landscape has forever changed – are you ready? Read the full article here!
Following IceCure’s accelerating global expansion, the company has received regulatory approval for the treatment of benign and cancerous tumors in many indications including for the breast, lung, bone and kidney. Through their new exclusive partner,Tecmed Africa, IceCure’s technology will lead the field in bringing cryoablation to South Africa. Read more
New Indian regulatory approval received for its cryoablation technology to destroy tumors in extensive indications, including for breast, lung, bone and kidney cancer. Read more.
IceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement with MTS Medical Technology
New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors. Read more.
New Territory in Singapore with Global Medical Leader, Terumo, Marks Successful Partnership Progress in Executing Milestone Distribution Agreement. Read more
IceCure Medical Continues Expansion in Asia; Receives Largest Purchase Order for ProSense™ Cryoablation System
Healthcare Institutions Continue to Adopt Minimally Invasive Oncology Solutions to Address Growing Demand and Provide Clinical and Economic Benefits. Read more
IceCure Receives FDA Clearance for Expanded Indications of Cryoablation Technology and Regulatory Approval of New MultiSense System; Plans to Increase U.S. Presence and Operations
Expands Use of Cryoablation Technology to Treat Liver and Kidney Tumors. Read more here
Ms. Levita is a medical device veteran and brings extensive financial and business management experience in developing successful companies. Read more here